GeneDx price target lowered to $150 from $180 at Jefferies

Jefferies lowered the firm’s price target on GeneDx (WGS) to $150 from $180 and keeps a Buy rating on the shares following Q4 results. The firm noted that the company’s Q4 earnings conference call was bullish on upside drivers for volumes and average selling prices, as well as competitive dynamics. While GeneDx has had a noisy start to 2026, coming out of Q4, the near- and long-term set-ups look better than ever, Jefferies told investors in a research note.